Clinical impact of ki-67 labeling index in non-small cell lung cancer

被引:93
作者
Jakobsen, Jan Nyrop [1 ]
Sorensen, Jens Benn [1 ]
机构
[1] Rigshosp, Finsenctr, Dept Oncol, DK-2100 Copenhagen, Denmark
关键词
Ki-67; MIB-1; Proliferation marker; NSCLC; Labeling index; Predictive marker; EARLY BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; BIOLOGICAL MARKERS; IMMUNOHISTOCHEMICAL MARKERS; PROLIFERATIVE ACTIVITY; NEUROENDOCRINE TUMORS; EXPRESSION; STAGE; SURVIVAL; P53;
D O I
10.1016/j.lungcan.2012.10.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ki-67 index is a marker of proliferation in malignant tumors. Studies from the period 2000 to 2012 on the prognostic and predictive value of ki-67 labeling index (LI) in non-small cell cancer (NSCLC) are reviewed. Twenty-eight studies reported on the prognostic value of ki-67 index with various endpoints. No consensus on the prognostic value of ki-67 LI was found among the published studies neither according to disease stage nor histological subtype. Comparison of studies is hampered by differences in patient populations, methodologies and cut-off values. Five studies explored the predictive value of ki-67 to chemotherapy and none revealed significant influence. Ki-67 index seems to be of prognostic influence in NSCLC although largely variable cut-off levels have been used in the various studies and standardization of methodology is required. The relative importance of ki-67 compared to newer biomarkers has not been explored. It is likely that a signature of several biomarkers in combination may be necessary to more sufficiently stratify patients to various treatment options than is currently possible, especially when it comes to the question of the optimal use of classical chemotherapy. A predictive impact of ki-67 to treatment in NSCLC remains unclear. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 81 条
[1]   Ki-67 proliferation index - Correlation with prognostic parameters and outcome in multiple myeloma [J].
Alexandrakis, MG ;
Passam, FH ;
Kyriakou, DS ;
Dambaki, K ;
Niniraki, M ;
Stathopoulos, E .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01) :8-13
[2]   Pulmonary atypical carcinoid: Predictors of survival in 106 cases [J].
Beasley, MB ;
Thunnissen, FBJ ;
Brambilla, E ;
Hasleton, P ;
Steele, R ;
Hammar, SP ;
Colby, TV ;
Sheppard, M ;
Shimosato, Y ;
Koss, MN ;
Falk, R ;
Travis, WD .
HUMAN PATHOLOGY, 2000, 31 (10) :1255-1265
[3]  
Bellotti M, 1997, MODERN PATHOL, V10, P1221
[4]   Clinically Relevant Characterization of Lung Adenocarcinoma Subtypes Based on Cellular Pathways: An International Validation Study [J].
Bryant, Christopher M. ;
Albertus, Daniel L. ;
Kim, Sinae ;
Chen, Guoan ;
Brambilla, Christian ;
Guedj, Mickael ;
Arima, Chinatsu ;
Travis, William D. ;
Yatabe, Yasushi ;
Takahashi, Takashi ;
Brambilla, Elisabeth ;
Beer, David G. .
PLOS ONE, 2010, 5 (07) :1-13
[5]   Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells [J].
Bullwinkel, J ;
Baron-Lühr, B ;
Lüdemann, A ;
Wohlenberg, C ;
Gerdes, J ;
Scholzen, T .
JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 206 (03) :624-635
[6]  
Cagini L, 2000, J SURG ONCOL, V74, P53, DOI 10.1002/1096-9098(200005)74:1<53::AID-JSO13>3.0.CO
[7]  
2-D
[8]  
Carbognani P, 2002, J CARDIOVASC SURG, V43, P545
[9]   Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas [J].
Carvalho, PED ;
Antonângelo, L ;
Bernardi, FD ;
Leao, LEV ;
Rodrigues, OR ;
Capelozzi, VL .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (11) :478-486
[10]   Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer [J].
Cavarga, I. ;
Kocan, P. ;
Boor, A. ;
Belak, J. ;
Zak, V. ;
Kluchova, Z. ;
Slavik, L. ;
Tkacova, R. .
NEOPLASMA, 2009, 56 (05) :414-421